NovaBridge Biosciences (NBP) EBITDA Margin (2019 - 2023)
NovaBridge Biosciences (NBP) posted quarterly EBITDA Margin of 789260.0% for Q4 2023, down 23279.43% quarter-over-quarter from 3375.87% in Q3 2023.
Powered by 
Analysis
NovaBridge Biosciences (NBP) EBITDA Margin (2019 - 2023) Analysis & Trends
NovaBridge Biosciences (NBP) has reported EBITDA Margin for 3 consecutive years, with 789260.0% the latest figure, recorded in Q4 2023.
- In Q4 2023, EBITDA Margin changed N/A year-over-year to 789260.0%; the TTM figure through Dec 2023 stood at 4903.88% (changed N/A YoY), while the FY2023 annual figure was 27673.99%, down 982002.0% from the prior year.
- EBITDA Margin fell to 789260.0% in Q4 2023 per NBP's latest filing, from 3375.87% in the prior quarter.
- Across five years, EBITDA Margin topped out at 5927.05% in Q4 2020 and bottomed at 789260.0% in Q4 2023.
- Historically, EBITDA Margin has averaged 159266.08% across 3 years, with a median of 3375.87% in 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 19.75% |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.36% |
| 10 | NovaBridge Biosciences | 199.33 Mn | 199.33 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | -789,260.00% |
| Sep 30, 2023 | -3,375.87% |
| Jun 30, 2023 | -7,578.62% |
| Dec 31, 2020 | 76.00% |
| Sep 30, 2019 | -2,042.94% |